Endoscopy 2014; 46(01): 75-78
DOI: 10.1055/s-0033-1344988
Case report/series
© Georg Thieme Verlag KG Stuttgart · New York

Hemospray treatment is effective for lower gastrointestinal bleeding

I. Lisanne Holster
1  Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
,
Enric Brullet
2  Department of Digestive Diseases, Hospital of Sabadell, Corporació Sanitaria Universitaria Parc Taulí, Sabadell, Spain and Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Spain
,
Ernst J. Kuipers
1  Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
,
Rafel Campo
2  Department of Digestive Diseases, Hospital of Sabadell, Corporació Sanitaria Universitaria Parc Taulí, Sabadell, Spain and Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Spain
,
Alberto Fernández-Atutxa
2  Department of Digestive Diseases, Hospital of Sabadell, Corporació Sanitaria Universitaria Parc Taulí, Sabadell, Spain and Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Spain
,
Eric T. T. L. Tjwa
1  Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

submitted 24 April 2013

accepted after revision 03 September 2013

Publication Date:
11 November 2013 (eFirst)

Acute lower gastrointestinal bleeding (LGIB) is diverse in origin and can be substantial, requiring urgent hemostasis. Hemospray is a promising novel hemostatic agent for upper gastrointestinal bleeding (UGIB). It has been claimed in a small series that the use of Hemospray is also feasible in LGIB. We aimed to expand our knowledge of the application of Hemospray for the treatment of LGIB in a wider range of conditions to further define the optimal patient population for this new therapeutic modality.

We analyzed the outcomes of nine unselected consecutive patients with active LGIB treated with Hemospray in two major hospitals in Europe. Initial hemostasis was achieved after Hemospray application in all patients. Rebleeding occurred in two patients (22 %) who were on acetyl salicylic acid and presented with spurting bleeds. These preliminary data show that Hemospray can be effective in the management of LGIB, but suggest cautious use for patients on antithrombotic therapy and spurting bleeds.